

## ITL BioMedical Announces Global Distribution Agreement for SSK with bioMérieux

[ITL BioMedical](#), a division of ITL (ASX: ITD) that sets industry standards for the innovative design and production of biological sampling systems for human and animal use, is pleased to announce it has signed a global, multi-year distribution agreement for its SampLok® Sampling Kit (SSK) with [bioMérieux](#) (Euronext: BIM), a multinational biotechnology company and supplier of bacterial screening test systems and ancillaries.

ITL BioMedical has partnered with bioMérieux for more than five years for the supply of SSK in the United Kingdom, generating \$11.5M in revenue. The new agreement will expand bioMérieux's distribution of SSK globally for three years with possible ongoing one year renewals.

bioMérieux has been a world leader in *in vitro* diagnostics for more than 50 years. The Company's global distribution strategy of SSK will include its existing network of more than 150 countries, 42 subsidiaries and many distributors.

SSK is a highly innovative product that is utilized in the blood banking market to transfer platelet samples during bacterial detection testing. It offers state of the art product design that facilitates product sampling for laboratory testing process efficiencies, safety in reducing potential for needlestick injuries and reduced biohazard waste, among other benefits. The device is compatible with standard blood component storage bags and culture bottles, offering controlled measurement of sample volume in various chamber sizes.

This builds upon SSK's recent inclusion in bioMérieux's multi-year tender award with UK's NHSBT, approval and implementation by OneBlood, a large U.S. blood bank, a contract extension with another large U.S. blood bank, and the grant of the SSK patent in the U.S. as well as Taiwan FDA approval.



**ITL Limited ABN 16 088 212 088**  
**Unit 1, 63 Wells Road**  
**Chelsea Heights, Victoria, 3196**

ITL is an innovative diversified medical technology company that creates and manufactures leading edge medical devices for Operating Theatres, Bloodbanks and laboratories.

ITL's patented medical devices are sold in over 50 countries and protect healthcare workers in millions of procedures annually.

ITL's wholly owned subsidiary MyHealthTest creates and markets highly innovative direct to consumer pathology testing for major chronic diseases.



Ranked 16<sup>th</sup> most Innovative Company by the AFR Innovative Companies Awards

**Australian Securities Exchange**  
Code: ITD

**Ordinary Shares**  
95,928,314

#### Board of Directors

Bill Mobbs	Executive Chairman
Mark Peatey	Non-executive Director
Andrew Turnbull	Non-executive Director

Trevor Doolan	Company Secretary & Chief Financial Officer
---------------	---

Trevor Doolan	Company Secretary
Phone:	+61 3 8773 3050
Email:	<a href="mailto:info@itl-limited.com">info@itl-limited.com</a>

[www.itl-limited.com](http://www.itl-limited.com)

<b>Media</b>	
Ben Knowles	Walbrook IR
Phone:	+61 426 277 760

Email: [ben.knowles@walbrookir.com.au](mailto:ben.knowles@walbrookir.com.au)



Innovating Technologies for Life

**ASX Announcement  
17 October 2016**

“This global distribution contract is an excellent achievement by ITL BioMedical,” commented Bill Mobbs, Executive Chairman of ITL. “bioMérieux is a highly respected company and its global reach will facilitate expansion of SSK sales.”

“The agreement is in line with ITL’s stated strategy at the start of the year to expand sales of SSK around the globe and we are confident that it should now outperform our expectations.”

Bill Mobbs

Executive Chairman

**About ITL BioMedical** – [ITLBioMedical.com](http://ITLBioMedical.com)

ITL BioMedical is a division of ITL that sets industry standards for the innovative design and production of biological sampling systems for human and animal use. The Division’s patented medical devices focus on safety and process efficiency for end-users and their blood donors and patients in healthcare markets worldwide. For more information visit [ITLBioMedical.com](http://ITLBioMedical.com).

#### **About bioMérieux**

##### **Pioneering Diagnostics**

bioMérieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. It’s products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms and preventing contamination in blood components, agri-food, pharmaceutical and cosmetic products. bioMérieux is listed on the Euronext Paris stock market

(Symbol: BIM/Reuters: BIOX.PA/Bloomberg: BIM.FP – ISIN: FR0010096479)

Corporate website: [www.biomerieux.com](http://www.biomerieux.com)

Industry website: [www.biomerieux-industry.com](http://www.biomerieux-industry.com)

For personal use only